 HAYWARD, Calif.--BUSINESS WIRE--Arcus Biosciences, Inc. NYSE:RCUS, an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented progression-free survival PFS and overall survival OS data in patients with advanced metastatic colorectal cancer mCRC from the ARC-3 study at the 2021 American Association for Cancer Research AACR Annual Meeting. ARC-3 was a Phase 11b, multicenter, open-label, dose-escalation and dose-expansion study that 